Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4938451 | 1.00 | HSD17B10 (0.34) | HSD17B10SMN1; SMN2CHRM2CHRM1PTPN1 | |
| SCHEMBL4936029 | 0.88 | MMP1 (0.36) | HSD17B10SMN1; SMN2PTPN1HDAC8 | |
| SCHEMBL6975179 | 0.88 | MMP1 (0.36) | HSD17B10SMN1; SMN2PTPN1HDAC8 | |
| SCHEMBL4936035 | 0.88 | MMP1 (0.36) | HSD17B10SMN1; SMN2PTPN1HDAC8 | |
| SCHEMBL4421983 | 0.82 | HSD17B10 (0.39) | HSD17B10SMN1; SMN2PTPN1 | |
| SCHEMBL4421987 | 0.82 | HSD17B10 (0.39) | HSD17B10SMN1; SMN2PTPN1 | |
| SCHEMBL4945427 | 0.82 | HSD17B10 (0.39) | HSD17B10SMN1; SMN2PTPN1 | |
| SCHEMBL4945424 | 0.82 | HSD17B10 (0.39) | HSD17B10SMN1; SMN2PTPN1 | |
| SCHEMBL5946005 | 0.82 | HSD17B10 (0.39) | HSD17B10SMN1; SMN2PTPN1 | |
| SCHEMBL5743539 | 0.82 | HSD17B10 (0.39) | HSD17B10SMN1; SMN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444225-B1 | PYRROLIDINE OXADIAZOLE- AND THIADIAZOLE OXIME DERIVATIVES BEING OXYTOCIN RECEPTOR ANTAGONISTS. | MERCK SERONO SA (CH) | 2012-10-10 | — | — | EP | disclosed |
| EP-1444225-B1 | PYRROLIDINE OXADIAZOLE- AND THIADIAZOLE OXIME DERIVATIVES BEING OXYTOCIN RECEPTOR ANTAGONISTS. | MERCK SERONO SA (CH) | 2012-10-10 | — | — | EP | disclosed |
| US-20080167318-A1 | Pharmaceutically active pyrrolidine derivatives | APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) | 2008-07-10 | — | — | US | disclosed |
| US-20070129381-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE ESTER DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-06-07 | — | — | US | disclosed |
| US-7211601-B2 | Pharmaceutically active pyrrolidine derivatives | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2007-05-01 | — | — | US | disclosed |
| US-7189754-B2 | Pyrrolidine ester derivatives with oxytocin modulating activity | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (AN) | 2007-03-13 | — | — | US | disclosed |
| US-20060229343-A1 | Pyrrolidine oxadiazole-and thiadiazole oxime derivatives being oxytocin receptor antagonists | APPLIED RESEARCH SYSTEMS ARS HOLDDING N.V. (NL) | 2006-10-12 | — | — | US | disclosed |
| US-7115639-B2 | Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-10-03 | — | — | US | disclosed |
| EP-1268419-B1 | PYRROLIDINE DERIVATIVES USEFUL AS BAX INHIBITORS | APPLIED RESEARCH SYSTEMS (AN) | 2006-06-21 | — | — | EP | disclosed |
| EP-1268418-B1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS | APPLIED RESEARCH SYSTEMS (AN) | 2006-06-14 | — | — | EP | disclosed |
| US-7018988-B2 | Pharmaceutically active pyrrolidine derivatives as Bax inhibitors | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-03-28 | — | — | US | disclosed |
| US-20040220238-A1 | Pyrrolidine oxadiazole-and thiadiazole derivatives | MERCK SERONO SA (CH) | 2004-11-04 | — | — | US | disclosed |
| US-20040147511-A1 | Pyrrolidine ester derivatives with oxytocin modulating activity | MERCK SERONO SA (CH) | 2004-07-29 | — | — | US | disclosed |
| US-20030212012-A1 | Pharmaceutically active pyrrolidine derivatives | MERCK SERONO SA (CH) | 2003-11-13 | — | — | US | disclosed |
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | MERCK SERONO SA (CH) | 2003-09-11 | — | — | US | disclosed |
| EP-1268418-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS | Applied Research Systems ARS Holding N.V. (AN) | 2003-01-02 | — | — | EP | disclosed |
| EP-1268419-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BAX INHIBITORS | Applied Research Systems ARS Holding N.V. (AN) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001074769-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-10-11 | — | — | WO | disclosed |
| WO-2001072705-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212012-A1 | Pharmaceutically active pyrrolidine derivatives | OXTR, CNR1, PRLHR | HSD17B10 1183/4885SMN1; SMN2 1513/4885CHRM2 602/4885 |
| US-20080167318-A1 | Pharmaceutically active pyrrolidine derivatives | OXTR, PRLHR, NR0B1 | HSD17B10 1166/4885SMN1; SMN2 1945/4885CHRM2 853/4885 |
| US-20040220238-A1 | Pyrrolidine oxadiazole-and thiadiazole derivatives | OXTR, PRLHR, PGF | HSD17B10 2124/4885SMN1; SMN2 2634/4885CHRM2 4035/4885 |
| US-20060229343-A1 | Pyrrolidine oxadiazole-and thiadiazole oxime derivatives being oxytocin receptor antagonists | OXTR, PRLHR, OXER1 | HSD17B10 2438/4885SMN1; SMN2 2249/4885CHRM2 3551/4885 |
| US-20070129381-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE ESTER DERIVATIVES | OXTR, GPR6, CNR1 | HSD17B10 1111/4885SMN1; SMN2 2251/4885CHRM2 451/4885 |
| US-20040147511-A1 | Pyrrolidine ester derivatives with oxytocin modulating activity | OXTR, OPRL1, OPRD1 | HSD17B10 1284/4885SMN1; SMN2 1734/4885CHRM2 698/4885 |
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | SUCNR1, PYCR1, GLS | HSD17B10 1885/4885SMN1; SMN2 459/4885CHRM2 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.